Inogen (INGN) Non-Current Deffered Revenue (2013 - 2026)
Inogen's (INGN) quarterly Non-Current Deffered Revenue came in at $3.2 million in Q1 2026, down 37.93% year-on-year from $5.1 million in Q1 2025, and down 12.02% on a QoQ basis from $3.6 million in Q4 2025.
Inogen (INGN) Non-Current Deffered Revenue (2013 - 2026) Analysis & Trends
Inogen (INGN) has 14 years of Non-Current Deffered Revenue data on file, last reported at $3.2 million in Q1 2026.
- On a quarterly basis, Non-Current Deffered Revenue fell 37.93% year-over-year to $3.2 million in Q1 2026; TTM through Mar 2026 was $3.2 million, a 37.93% decrease from a year earlier, with the FY2025 full-year figure at $3.6 million, down 37.31% from the prior year.
- Non-Current Deffered Revenue for Q1 2026 stood at $3.2 million, down from $3.6 million in the prior quarter.
- Over the last five years, Non-Current Deffered Revenue for INGN reached as high as $11.5 million in Q1 2022 and fell as low as $3.2 million in Q1 2026.
- Historically, Non-Current Deffered Revenue has averaged $7.5 million across 5 years, with a median of $7.6 million in 2024.
- Across the five-year window, Non-Current Deffered Revenue dropped 2.81% in 2022 and plunged 37.93% in 2026, its largest moves.
- Year by year, Non-Current Deffered Revenue stood at $10.4 million in 2022, then declined by 20.89% to $8.2 million in 2023, then plunged by 30.14% to $5.7 million in 2024, then slumped by 37.31% to $3.6 million in 2025, then retreated by 12.02% to $3.2 million in 2026.
- Per Business Quant data, the three most recent Non-Current Deffered Revenue figures were $3.2 million in Q1 2026, $3.6 million in Q4 2025, and $4.1 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | - |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | - |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | - |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | - |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | - |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | - |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 512.79 Mn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | - |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Inogen | 172.68 Mn | 62.51 Mn | 37.86 Mn | 3.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.17 Mn |
| Dec 31, 2025 | 3.60 Mn |
| Sep 30, 2025 | 4.08 Mn |
| Jun 30, 2025 | 4.59 Mn |
| Mar 31, 2025 | 5.11 Mn |
| Dec 31, 2024 | 5.75 Mn |
| Sep 30, 2024 | 6.44 Mn |
| Jun 30, 2024 | 7.07 Mn |
| Mar 31, 2024 | 7.61 Mn |
| Dec 31, 2023 | 8.23 Mn |
| Sep 30, 2023 | 8.88 Mn |
| Jun 30, 2023 | 9.35 Mn |
| Mar 31, 2023 | 9.80 Mn |
| Dec 31, 2022 | 10.40 Mn |
| Sep 30, 2022 | 11.03 Mn |
| Jun 30, 2022 | 11.40 Mn |
| Mar 31, 2022 | 11.51 Mn |
| Dec 31, 2021 | 11.86 Mn |
| Sep 30, 2021 | 12.14 Mn |
| Jun 30, 2021 | 12.19 Mn |